MedTrace Logo

A Safety and Immunogenicity Study of Inactivated SARS-CoV-2 Vaccine (Vero Cells) in Healthy Population Aged 18 Years and Above(COVID-19)

NCT04758273 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 180

Last updated 2021-02-17

No results posted yet for this study

Summary

This study is a randomized, double-blinded, and placebo controlled phase Ⅰ clinical trial of the SARS-CoV-2 inactivated vaccine to evaluate the safety and immunogenicity of the experimental vaccine in healthy adults ⩾18 years.

Conditions

Interventions

BIOLOGICAL

medium dosage inactivated SARS-CoV-2 vaccine

medium dosage

BIOLOGICAL

high dosage inactivated SARS-CoV-2 vaccine

high dosage

BIOLOGICAL

Placebo

placebo

Sponsors & Collaborators

  • Shenzhen Kangtai Biological Products Co., LTD

    collaborator INDUSTRY

  • Jiangsu Province Centers for Disease Control and Prevention

    collaborator NETWORK

  • Beijing Minhai Biotechnology Co., Ltd

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-10-07
Primary Completion
2021-06-30
Completion
2022-02-28

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04758273 on ClinicalTrials.gov